When cytokinin-autonomous tobacco BY-2 cell cultures are transferred into 2,4-dichlorophenoxyacetic acid (2,4-D)-deprived medium, amyloplast development is initiated. Using this in vitro amyloplast-inducing system, the role of cytokinins in amyloplast formation was investigated. We show that addition of lovastatin, an inhibitor of mevalonate synthesis, to amyloplast-inducing medium reduced starch accumulation. Microscopic observation also revealed that lovastatin treatment decreased starch deposition; however, the overall morphologies of cells and plastids were less affected than control cell cultures. In addition, lovastatin lowered the transcription level of the ADPglucose pyrophosphorylase small subunit (AgpS) gene. Application of mevalonate or zeatin dramatically restored the decrease in starch deposition, and restored AgpS mRNA accumulation. Moreover, addition of other molecules with cytokinin activity, such as adenine-and phenylurea-type compounds, restored starch accumulation and AgpS transcript levels, whereas other isopentenyl pyrophosphatederived phytohormones did not. Liquid chromatographymass spectrometry/mass spectrometry quantification of endogenous cytokinins revealed that endogenous cytokinins increased when BY-2 cells were transferred into 2,4-Ddeprived medium from conventional medium containing 2,4-D. In addition, lovastatin treatment decreased endogenous cytokinins to some extent when cultured under 2,4-Ddeprived conditions. Our results suggest that both 2,4-D deprivation and an increase in endogenous cytokinins have important roles in accelerating the changes in plastid morphology, starch accumulation, and AgpS gene expression.
Introduction
Amyloplasts are mature plastids that are found in differentiated plant cells, including root caps and storage tissues, such as cotyledons, endosperm, and tubers. They play important roles in the synthesis and accumulation of starch as a carbohydrate reserve in storage tissue, and in graviperception in root cap cells. As amyloplasts are intimately involved in carbon metabolism in plants, analysis of the mechanisms that control amyloplast formation is a key step toward understanding the regulation of storage potential and sink-source relationships in plants. Many of the enzymes involved in starch synthesis have been elucidated (reviewed in Smith et al. 1997 ), but the mechanisms that regulate amyloplast development remain unknown.
Generally, starch storage organ development occurs in a series of specific temporal and spatial steps, which occur in phase with cell division and differentiation. These phases cannot be separated, and often occur simultaneously. Moreover, storage organs are highly organized and complex, making it difficult to analyze the mechanisms that control starch storage in heterotrophic tissues. To overcome these problems, we used a system for inducing amyloplast formation in cultured Bright Yellow-2 (BY-2) tobacco (Nicotiana tabacum) cells (Miyazawa et al. 1999) . Conventionally, tobacco BY-2 cells are grown in a liquid culture medium containing auxin (2,4-dichlorophenoxyacetic acid; 2,4-D), and are characterized by their homogeneity and high growth rate, which are necessary in cell biology studies (Nagata et al. 1992, Geelen and Inzé 2001) . When BY-2 cells are transferred to auxin-depleted medium, amyloplast formation is synchronously induced in 2 d (Miyazawa et al. 1999) . In this system, amyloplast formation is induced by the depletion of 2,4-D, and starch accumulation is facilitated by the addition of cytokinin (benzyladenine; BA). However, the cytokinin-autonomous nature of BY-2 cells prevented us from determining the role of cytokinins in amyloplast formation.
The main aim of this study was to elucidate the effect of cytokinins on amyloplast formation in BY-2 cells. In order to inhibit cytokinin biosynthesis in BY-2 cells, we used lovastatin, which inhibits the reduction of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonic acid. Crowell and Salaz (1992) suggested that low lovastatin concentrations specifically inhibit the isoprenoid side-chain addition in zeatin synthesis in BY-2 cells. Indeed, lovastatin treatment blocks the progression of the plant cell cycle (Hemmerlin and Bach 1998, Laureys et al. 1998) , due to inhibition of the zeatin synthesis pathway and the accumulation of cells at the G 2 /M transition (Laureys et al. 1998) . We investigated the effect of lovastatin on cell proliferation, amyloplast formation, endogenous cytokinin content, and the synthesis of ADP-glucose pyrophosphorylase small subunit mRNAs, which encode a protein that is indispensable for starch synthesis in the presence of lovastatin. Our results show that lovastatin blocked amyloplast formation in BY-2 cells, and accumulation of endogenous cytokinin content, effects that was negated by addition of mevalonic acid and zeatin. Lovastatin inhibits isopentenyl pyrophosphate (IPP) production by blocking mevalonic acid synthesis; the IPP pools, both cytosolic and plastidic, might be altered so that the production of both zeatin and phytosterols and many other isoprenoid-derived compounds is assumed to be inhibited. Therefore, we further investigated whether two other phytohormones, gibberellin and brassinolide, which are derived from IPP, could overcome the inhibition caused by lovastatin treatment. Neither gibberellin nor brassinolide reversed the inhibition caused by lovastatin treatment. In contrast, addition of either BA or N-(2-chloro-4-pyridyl)-N¢-phenylurea (KT30) restored the decrease in starch content. These results suggest that synthesis of mevalonate-derived compounds, probably cytokinins, is required for amyloplast formation in BY-2 cells.
Results

Effects of lovastatin treatment on amyloplast formation in BY-2 cells
To investigate the effect of lovastatin on amyloplast formation, we added lovastatin to both conventional medium (Cmedium) and F-medium (C-medium without phytohormones), and examined cell multiplication and starch content. Because lovastatin inhibits mevalonate biosynthesis, the products of which might have broad effects on plant growth and development, we chose a concentration of 1 mM for further investigation, since at this level cytokinin production is assumed to be specifically inhibited in BY-2 cells (Crowell and Salaz 1992) . In C-medium, the addition of 1 mM lovastatin reduced cell multiplication, which was reversed by adding either 1 mM zeatin or 6 mM mevalonic acid (Fig. 1 ). This indicates that lovastatin inhibits cytokinin synthesis at this concentration, as described in Crowell and Salaz (1992) . No obvious changes in starch accumulation were observed among these cultures. In contrast, in F-medium, amyloplast development proceeded, and starch accumulated. When BY-2 cells transferred to F-medium were treated with lovastatin, a significant decrease in starch content was observed, whereas there were no obvious changes in cell multiplication (Fig. 1 ). This decrease in starch content could be reversed by adding either zeatin or mevalonic acid. The recovery of starch accumulation by mevalonic acid addition confirmed that lovastatin blocks mevalonate synthesis, and that mevalonate synthesis is required during amyloplast formation in BY-2 cells. Moreover, addition of zeatin alone restored the starch accumulation, indicating that endogenous cytokinins, which are necessary for starch accumulation, are reduced by lovastatin application during amyloplast formation in BY-2 cells.
Since amyloplast formation in BY-2 cells involves drastic morphological changes not only in cells, but also in plastids (Miyazawa et al. 1999) , we observed lovastatin-treated BY-2 cells to examine the effects of lovastatin on cell, plastid, and starch granule morphology. When BY-2 cells were transferred to F-medium, amyloplast development proceeded and obvious starch granules were observed (Fig. 2a-c) , but when BY-2 cells were transferred into lovastatin-containing F-medium, amyloplast development was inhibited, and starch granules inside the plastids were relatively small ( Fig. 2d-f) . However, the overall shapes of cells and plastids of lovastatin-treated cells were similar to those of control cells, which are distinct from those of cells cultured in C-medium, as described previously (Miyazawa et al. 1999 , Miyazawa et al. 2001 ). Adding either mevalonate or zeatin reversed the decrease in starch accumulation in lovastatin-treated cells (Fig. 2g-l) . These results corre- Fig. 1 Effects of lovastatin on cell multiplication and starch accumulation. Changes in cell multiplication (top) and starch content per cell (bottom) were monitored after culturing BY-2 cells under various conditions for 48 h. Cell multiplication is expressed as a relative value, where the number of cells at 0 h was set as 1. Data are the means of three independent experiments. Vertical bars represent the standard deviation. The four columns at the left show the results when cultured in C-medium with various treatments, including control (blank solution added), 1 mM lovastatin, 6 mM mevalonate + 1 mM lovastatin, and 1 mM zeatin + 1 mM lovastatin; whereas the four columns at the right show the results when cultured in F-medium with the same treatments as in C-medium. Open bars, control cells; solid bars, cells treated with 1 mM lovastatin; gray bars, cells treated with 1 mM lovastatin and 6 mM mevalonate; hatched bars, cells treated with 1 mM lovastatin and 1 mM zeatin.
spond well with the starch quantification shown in Fig. 1 . From these results, we hypothesized that a decrease in endogenous cytokinins by lovastatin treatment inhibits starch accumulation in BY-2 cells.
To confirm this hypothesis, we quantified endogenous cytokinin content using liquid chromatography-mass spectrometry/mass spectrometry (LS-MS/MS) ( Table 1) . As a previous report showed that zeatin and zeatin riboside were reduced by lovastatin treatment, and this decrease inhibited cell cycle progression (Laureys et al. 1998 ), we investigated endogenous zeatin and zeatin riboside content. Upon quantification, we separated trans-, and cis-isomers of zeatin and zeatin riboside, to determine whether contents of these isomers are altered by lovastatin treatment, because activities differ between these isomers; the cis-isomer is usually much less active than its trans counterpart (Mok and Mok 2001) . Three independent experiments were performed, with similar results. The results of two of the three experiments are shown. Surprisingly, the trans-zeatin riboside content of F-medium-cultured (amyloplast developed) BY-2 cells was significantly higher (3-to 5- Fig. 2 Effects of lovastatin on amyloplast development. Forty-eight-hour-old cells transferred into F-medium with 1 mM lovastatin (d-f), 1 mM lovastatin + 6 mM mevalonate (g-i), and 1 mM lovastatin + 1 mM zeatin treatment (j-l) were harvested and compared microscopically with control cells (a-c). a, b, d, e, g, h, j, and k show iodine-stained BY-2 cells observed under bright-field microscopy, whereas c, f, i, and l show plastids observed under phase-contrast microscopy. a, d, g, and j; b, e, h, and k; and c, f, i, and l are at the same magnifications. b, e, h, and k are magnifications of the cells shown in a, d, g, and j. Arrowheads in c, f, i, and l show starch granules. The bars in j, k, and l represent 50 mm, 20 mm, and 5 mm, respectively.
fold) than that of C-medium-cultured (proliferating) cells. Moreover, cytokinin levels, particularly trans-zeatin riboside, were reduced (40 to 57% of the F-medium-cultured cells) by lovastatin treatment, which was reversed by mevalonate addition. These results suggest that both 2,4-D deprivation and an increase in endogenous cytokinin content are required for amyloplast formation in BY-2 cells.
Furthermore, we investigated the gene expression required for starch accumulation by RNA gel blot analysis (Fig. 3) . We chose the ADP-glucose pyrophosphorylase small subunit (AgpS) cDNA as a probe to detect transcripts, since ADPglucose pyrophosphorylase is widely believed to catalyze the first rate-limiting step in starch biosynthesis (Martin and Smith 1995) , and accumulation of its transcripts is strikingly decreased by 2,4-D addition and increased by cytokinin addition (Miyazawa et al. 1999) . As shown in Fig. 3 , accumulation of AgpS transcripts was relatively lower in lovastatin-treated BY-2 cells than in control cells, whereas actin mRNA levels fluctuated little. Once again, this decrease in transcript levels was overcome by adding either mevalonate or zeatin. This result suggests that endogenous cytokinin contents affect AgpS transcript levels to control the rate of starch synthesis during amyloplast formation in BY-2 cells.
The decrease in starch content and starch synthesis gene expression caused by lovastatin is reversed only by cytokinins and not by other isopentenyl pyrophosphate-derived phytohormones
To assess the involvement of cytokinins in amyloplast formation in BY-2 cells, we investigated whether other cytokininlike molecules with chemically different structures can reverse the effect of lovastatin treatment on amyloplast formation. We tested two compounds known to have cytokinin activity: BA, an adenine-type cytokinin; and KT30, a phenylurea-type cytokinin. Both BA and KT30 effectively reversed the starch accumulation that was inhibited by lovastatin (Fig. 4a) . In addition, we tested whether these compounds could restore the original transcript level of AgpS (Fig. 4b) . Both BA and KT30 were able to increase transcript levels of AgpS that had been reduced by lovastatin treatment. As inhibition of mevalonate synthesis leads to a decrease in IPP content, deleterious alterations of IPP pools could occur. Therefore, we investigated the effects of two other phytohormones, gibberellic acid (GA 3 ) and brassinolide (BL), which are derived from IPP. As shown in Fig. 4a and 4b, neither GA 3 nor BL could reverse the reduction in starch accumulation and AgpS transcript levels triggered by lovastatin application. A slight increase in AgpS transcript levels was observed when BL was applied, although the level remained significantly lower than that observed in control cells. From these results, we concluded that the inhibition of amyloplast formation in BY-2 cells is caused by the reduction of endogenous cytokinin following lovastatin treatment, and that enhanced accumulation of endogenous cytokinin in 2,4-Ddepleted conditions is necessary for amyloplast formation in BY-2 cells. Fig. 3 Comparison of AgpS transcript levels under lovastatin-treated conditions. Total RNA was extracted from 48-h-old BY-2 cells in Fmedium, supplied with blank solution (control), 1 mM lovastatin (+LV), 1 mM lovastatin + 1 mM zeatin (+LV, +Z), and 1 mM lovastatin + 6 mM mevalonate (+LV, +MA), and subjected to RNA gel blot analysis. Each lane was loaded with 5 mg of total RNA to detect AgpS and actin, and 0.1 mg of total RNA to detect rRNA. Hybridization signals for transcripts of AgpS (top), actin (middle), and 26S rRNA (bottom) are shown.
Discussion
Previously, we reported that excess cytokinins under auxin-deprived conditions enhance starch deposition and AgpS transcript accumulation (Miyazawa et al. 1999) . However, the exact role of endogenous cytokinin in amyloplast formation remained unclear, due to the cytokinin-autonomous nature of BY-2 cells. It was thought that treatment with an inhibitor of cytokinin biosynthesis would add new insights to the exact role of endogenous cytokinin in amyloplast formation. In tobacco BY-2 cells, lovastatin, an inhibitor of HMG-CoA reductase, has recently been used to reduce endogenous cytokinin content (Laureys et al. 1998 , Laureys et al. 1999 . In this paper, we investigated the role of endogenous cytokinin in amyloplast formation, using lovastatin as a tool. Since mevalonate-derived compounds, such as phytosterols, have several indispensable roles in plant growth and development, we added lovastatin at a concentration of 1 mM, a treatment that specifically inhibits cytokinin biosynthesis (Crowell and Salaz 1992) . In Cmedium, lovastatin treatment effectively inhibited cell multiplication, an effect that could be reversed by adding either zeatin or mevalonate. No obvious changes in starch content between lovastatin-treated cells and control cells were observed. When zeatin was added in addition to lovastatin when 2,4-D was supplied, a slight increase in starch content was observed. This increase can be regarded as an effect of excess zeatin content, because a slight increase in starch content is also observed when cytokinin alone is added to C-medium-cultured BY-2 cells (Sakai et al. 1996) . In contrast, when BY-2 cells were cultured in F-medium, cell multiplication was repressed and starch accumulation occurred. Under 2,4-D-depleted conditions, lovastatin treatment inhibited starch accumulation, as compared to control cells. This inhibition of starch accumulation was reversed by adding either 1 mM zeatin or 6 mM mevalonate. These results were confirmed by microscopic observations. The overall cell shapes of control cells and lovastatin-applied cells were similar; however, the shapes of plastids and the sizes of starch granules were quite different (i.e. relatively large and empty stroma with fewer, and smaller, starch granules). This morphological tendency in cells and plastids was also observed when BY-2 cells with developing amyloplasts were treated with chloramphenicol (Miyazawa et al. 2000) , but is strikingly different from proplastids observed when 2,4-D is supplied (Miyazawa et al. 2001) .
We further investigated the in vivo cytokinin content using LC-MS/MS. Because zeatin and zeatin riboside have been proved to be reduced by lovastatin treatment, and this decrease inhibited cell cycle progression (Laureys et al. 1998 ), we quantified endogenous zeatin and zeatin riboside content. We separated trans-, and cis-isomers of zeatin and zeatin riboside content, whether contents of these isomers are altered by lovastatin treatment, because activities differ between these isomers; the cis-isomers are usually much less active than their trans counterparts (Mok and Mok 2001) . To our surprise, the trans-zeatin riboside content under 2,4-D-depleted conditions was 3-to 5-fold higher than that under 2,4-D-supplied conditions. This indicates that 2,4-D-deprived cells require a high concentration of cytokinin for amyloplast formation. This hypothesis is further confirmed by the quantification of cytokinin in lovastatin-treated cells. Lovastatin treatment slightly, but significantly, reduced the endogenous trans-zeatin riboside content (approximately 50% to 2,4-D-depleted condition), although other substances were rarely detectable in most samples. We also observed the accumulation of cis-zeatin riboside by lovastatin treatment. It is likely that this cis-isomer comes from other pathways, at least under lovastatin-treated conditions. Indeed, the indirect pathway of cytokinin synthesis has been thought to be the breakdown of cytokinin-containing tRNAs, and cis-isomer of cytokinin is the predominant form in tRNAs (reviewed in Prinsen et al. 1997) . Bassil et al. (1993) characterized that cis-trans-isomerase of zeatin in Plaseolus, which can also use cis-zeatin riboside as substrate. Although we have not identified the activity of cis-trans-isomerase of zeatin, the decrease of the cis-isomer of zeatin riboside under 2,4-D-deprived conditions might result from the change in activities of this enzyme by 2,4-D concentration. However, the exact reason why lovastatin treatment caused a slight but defi- nite accumulation of cis-zeatin riboside remains unknown. It has been reported that in synchronized BY-2 cell cultures, cytokinin peaks at three phases: G 1 , S, and G 2 /M (Redig et al. 1996) . Laureys et al. (1998) , Laureys et al. (1999) showed that the decrease in cytokinin content following lovastatin application restricts the G 2 /M transition, but not the G 1 /S transition. Since amyloplast formation occurs when 2,4-D-depleted cells cease cell proliferation at G 1 phase (Miyazawa et al. 1999) , the accumulation of cytokinin might correspond to the peak observed at G 1 in 2,4-D-supplied synchronized cultures. Lovastatin treatment of cells at G 1 phase resulted in a marked decrease in endogenous cytokinin content under both 2,4-Dsupplied and 2,4-D-depleted conditions; however, the effects were quite different. Under 2,4-D-supplied conditions, decrease in cytokinin content did not inhibit further progression of the cell cycle (Laureys et al. 1999) , whereas under 2,4-D-depleted conditions, decrease in trans-zeatin riboside content inhibited further amyloplast formation. Our results show that feeding either mevalonate or cytokinins (zeatin, BA, KT30) to lovastatin-treated cells negated the effect of lovastatin on starch accumulation and AgpS gene expression. Together with our quantification data, this strongly suggests that the reduced starch accumulation seen following lovastatin treatment is caused by reduced levels of endogenous cytokinin.
Although a significant decrease in endogenous cytokinin content was observed in the presence of lovastatin, the relative decrease in cytokinin content was smaller than expected. Two possible explanations for this unexpected rate of decrease can be considered. The first is that the concentration of lovastatin was not high enough to completely inhibit the synthesis of cytokinins. As mentioned above, high concentrations of lovastatin are not suitable for analyzing the relationship between cytokinin and amyloplast development, since the treatment causes irreversible effects in addition to decreasing cytokinin content. The other possibility is that endogenous cytokinins are synthesized via other pathways in lovastatin-treated cells. In fact, dimethylallyl pyrophosphate, a precursor of the zeatin side chain, can be synthesized via a non-mevalonate pathway in plant cells (Lichtenthaler 1999 , Rohmer 1999 . The report that a mutation in 1-deoxy-D-xylulose-5-phosphate synthase gene, which causes a defect in the non-mevalonate pathway, does not affect amyloplast structures in Arabidopsis root cells (Estévez et al. 2000) , indicates that the non-mevalonate pathway does not affect amyloplast development. Although this does not directly mean that the non-mevalonate pathway is inactive in amyloplast-induced BY-2 cells, we conclude that the unexpected rate of decrease in cytokinin content resulted from a sublethal concentration of lovastatin. It is evident that plant cells utilize mevalonate-derived isoprenoid as a zeatin sidechain donor (Laureys et al. 1998 (Laureys et al. , Åstot et al. 2000 ; however, the contribution of the non-mevalonate pathway to cytokinin biosynthesis in BY-2 cells should be clarified, at least under mevalonate-restricted conditions. Analyses using inhibitors such as fosmidomycin may reveal the in vivo roles of the nonmevalonate pathway in cytokinin biosynthesis and amyloplast formation.
To confirm the necessity of increased levels of endogenous cytokinin for amyloplast formation, we investigated whether other IPP-derived phytohormones could restore starch accumulation following lovastatin treatment. In addition to lovastatin, we applied GA 3 (to final concentrations of 10 mM and 1 mM) and BL (to final concentrations of 1 mM and 0.1 mM); GA 3 and BL are derived from the non-mevalonate and mevalonate pathways, respectively. Application of GA 3 did not reverse the decrease in starch content caused by lovastatin treatment. As gibberellin is synthesized via the non-mevalonate pathway, this is in accordance with the result that the non-mevalonate pathway does not seem to affect amyloplast formation in Arabidopsis root cap cells. Similarly, application of BL, which is derived from mevalonate, did not rescue the reduced starch content of lovastatin-treated cells. Since both BA and KT30, which has no isoprenoid group to donate, not isoprenoids derived from zeatin, but compounds that have cytokinin activities have effects on amyloplast formation. Laureys et al. (1998) observed a stringent structure-specific effect of zeatin, rather than just a general effect of cytokinins, at the G 2 -M transition in tobacco BY-2 cells. Since not only zeatin but also other cytokinins (BA, KT30) restored starch accumulation in lovastatintreated BY-2 cells, our results indicate that the mechanisms involving cytokinin during amyloplast formation differ from those in cell cycle progression.
The reduction of the AgpS mRNA levels under lovastatintreated conditions revealed that accumulation of AgpS can be decreased both by increasing exogenous 2,4-D content (Miyazawa et al. 1999 , Miyazawa et al. 2002 and by decreasing endogenous cytokinin content. Since the allosteric properties of AGPase are the primary factors regulating the enzyme's activity (Greene and Hannah 1998) , changes in AgpS transcript levels under various culture conditions, such as lovastatin treatment, do not directly explain the alteration in starch content. However, our finding of a correlation between AgpS transcript levels and starch content suggests that the endogenous cytokinin content can regulate the level of transcription of the AgpS gene, either directly or indirectly, thereby affecting the rate of starch accumulation.
Based on these considerations, we conclude that BY-2 cells increase their levels of endogenous cytokinin, derived from the mevalonate pathway, under 2,4-D-deprived conditions, and that this increase in endogenous cytokinin content accelerates the changes in plastid morphology, starch accumulation, and AgpS gene expression.
Materials and Methods
Preparation of chemicals
Lovastatin was purchased from Calbiochem (San Diego, CA, U.S.A.), and mevalonate lactone was bought from Sigma (St. Louis, MO, U.S.A.). The lactone rings of lovastatin and mevalonate lactone were hydrolyzed in ethanolic NaOH (15% (v/v) ethanol, 0.25% (w/v) NaOH) before use, as described in Crowell and Salaz (1992) . KT30 was a gift from Kyowa Hakko Kogyo Co. Ltd. (Tokyo, Japan).
Cell culture
Tobacco (N. tabacum) BY-2 cell suspension cultures were maintained in C-medium described in Nagata et al. (1992) . To induce amyloplast formation, 5 ml of a suspension of stationary-phase cells grown for 8 d in C-medium were transferred into F-medium, as described previously (Miyazawa et al. 1999) . Hydrolyzed lovastatin solution was added to a final concentration of 1 mM. For the control culture, a solution containing only 15% (v/v) ethanol and 0.25% (w/v) NaOH (blank solution) was added in the place of lovastatin solution.
Microscopic observations and measuring cell number and starch content
To stain starch granules in the BY-2 cells, the cell suspension was mixed with Lugol's solution (Merck, Darmstadt, Germany) and observed under a microscope immediately after staining. For phasecontrast microscopic observations, cells were treated with a solution of 0.6 M mannitol, 1% cellulase YC (Kikkoman Co. Ltd., Tokyo, Japan), and 0.1% pectolyase Y23 (Kikkoman Co. Ltd., Tokyo, Japan) for 90 min to make protoplasts. The protoplasts were then fixed with 1% (w/v) glutaraldehyde and observed under a microscope equipped with phase contrast optics. The number of cells per ml of culture was counted under a microscope. The starch content was quantified by the phenol-sulfuric acid method after extraction with hot water and perchloric acid, as described previously (Miyazawa et al. 2001) .
RNA extraction and RNA gel blot analysis
RNA was extracted using TRIzol reagent (Invitrogen Corp., Carlsbad, CA, U.S.A.), according to the manufacturer's instructions. Then, 5 mg of total RNA was denatured with glyoxal and subjected to gel electrophoresis according to standard procedures (Sambrook et al. 1989) . The RNA was transferred to Hybond-XL membrane (Amersham Pharmacia Biotech, U.K.). Cloned DNA fragments of cytoplasmic rRNA of rice (Suzuki et al. 1992) , and cDNA fragments of AgpS and actin (Miyazawa et al. 2002) , were used as probes to detect their transcripts. The blots were hybridized following standard procedures (Sambrook et al. 1989 ).
Extraction, purification and quantification of cytokinins
Authentic and deuterium-labeled cytokinins were used as standards. Internal standards were purchased from Apex Organics (Honiton, U.K.). The LC system was a Model 1100 series liquid chromatograph equipped with a binary pump, a vacuum degasser, a thermostatted column compartment and a thermostatted autosampler, all from Agilent (Palo Alto, CA, U.S.A.). The LC separations were performed at 25°C on a CAPCELL PAK MG column (5 mm, 250´2.0 mm -inner diameter) from Shiseido (Tokyo, Japan). The mobile phase flow rate was 0.2 ml min -1 with 15% (v/v) acetonitrile/ 85% (v/v) 0.1% (w/w) acetic acid. MS detection was carried out using an Applied Biosystems Sciex API-2000 triple quadrupole instrument (Thornhill, ON, Canada) equipped with a Turbo ion spray interface. The fragment ion and precursor ion pair with the highest S/N ratio (trans-zeatin and cis-zeatin = 220/136, trans-zeatin riboside and ciszeatin riboside = 352/220) were selected for further MS detection in multiple reaction monitoring mode. As multiple reaction monitoring is based on the transition involving a pseudo-molecular ion and a specific fragment ion, high detection selectivity and high S/N ratios can be obtained, providing a clean mass chromatogram. LC-MS/MS system control and collection of the data were performed with an Apple Macintosh computer (Austin, TX, U.S.A.) equipped with MassChrom v 1.1 software from PE Sciex. The sample was ground in liquid nitrogen. Then 10 ml of 80% methanol were added to 1 g FW of each sample, and homogenized for extraction, followed by addition of an internal standard; 5´10 -11 mol of deuterium-labeled trans-zeatin (d5Z) was added in each extraction. After centrifugation at 10,000´g for 10 min at 4°C, the supernatant was filtered and diluted in 10 volumes of water. The diluents were loaded onto solid-extraction cartridges (OASIS-HLB, 6 cc 200 mg, Waters, Milford, MA, U.S.A.) that had been preconditioned with 80% methanol and water. After loading the sample, the column was washed with methanol-water (pH 7, 10 : 90 v/v) and methanol-water (pH 3, 10 : 90 v/v) solutions. Finally, the cytokinins were eluted with methanol-water (pH 3, 40 : 60 v/v). The eluate was concentrated by rotary evaporation (35°C, 10 min) and applied to an LC-ESI/MS/MS system.
